Developer docs
API playgroundTry for free, no card

Search company profiles

SentreHEART

Full company profile

uuid0003sli

Namestring
SentreHEART
Legal namestring
AtriCure, Inc.
Websiteurl
sentreheart.com
Company typeenum
Public
Founded yearint
2005
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cardiac medical devices, tissue closure solutions, remotely delivered sutures, surgical closure devices, atrial appendage management
Industry2 codes
PRIMARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHALAD
Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Medical Devices
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1cryoICE
Description

Cryoablation probes for surgical procedures

atricure.com
+7 more records
Core offering1 text field

SentreHEART is a medical device company developing tissue closure solutions that give physicians control over remotely delivered sutures. The company focuses on cardiac intervention devices, including hybrid atrial fibrillation therapy devices, epicardial access instruments, and left atrial appendage management products used during cardiac surgery and electrophysiology procedures.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

AtriCure offers a comprehensive portfolio of medical devices for cardiac surgery focused on two main therapy areas: atrial fibrillation (AFib) treatment and post-operative pain management. The product portfolio includes ablation systems (radiofrequency and cryoablation), left atrial appendage management devices (AtriClip family), and cryo nerve block probes for pain management. Key product lines include the Isolator Synergy ablation clamps and pens, cryoICE cryoablation systems, the EPi-Sense device for Hybrid AF Therapy, and the full AtriClip device family for left atrial appendage exclusion. The company also provides minimally invasive surgical instruments and a Multifunctional Ablation Generator (MAG). The portfolio is organized around therapy platforms: Concomitant Surgical Ablation, Hybrid AF Therapy, Hybrid Total Thoracoscopic Therapy, Cryo Nerve Block Therapy, and Left Atrial Appendage Management (LAAM).

Product and service1 record
1EPi-Sense Device
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Robotic magnetic navigation system provider for cardiac ablation procedures, supplying enabling technology to electrophysiology labs where SentreHEART's closure devices may be deployed.

TypeEmerging player
Description

Specialist structural heart occlusion company developing LAA and other cardiac closure devices, providing a direct emerging competitor in the same closure-device category as SentreHEART.

TypeBroad incumbent
Description

World-leading cardiovascular device company with electrophysiology, surgical ablation, and cardiac rhythm management businesses directly adjacent to SentreHEART's procedural domain.

TypeBroad incumbent
Description

Large-cap medical device company whose Watchman is the market-leading endocardial LAA closure device, addressing the same stroke-prevention unmet need served by SentreHEART's closure technology.

TypeEmerging player
Description

Private LAA closure developer (CLAAS system) competing in the same left-atrial appendage closure space as SentreHEART with a next-generation conformable device design.

6Johnson & Johnson (Biosense Webster)
TypeBroad incumbent
Description

Biosense Webster is the dominant electrophysiology franchise globally; competes in ablation and LAA management pipelines that overlap with SentreHEART's target procedures.

TypeRegional player
Description

China-based cardiovascular and structural heart device company with an LAA occluder line (LAmbre) covering the same clinical indication served by SentreHEART, primarily in the Asia-Pacific market.

TypeEmerging player
Description

Structural heart company developing implant-based devices for cardiovascular applications; a comparable small-stage developer with niche mechanical solutions addressing cardiac procedural needs.

TypeBroad incumbent
Description

NASDAQ-listed atrial fibrillation and pain management medical device company; competes directly in LAA exclusion (AtriClip) and surgical ablation and is the only natural strategic acquirer given its overlap with SentreHEART's tissue-closure focus.

10Abbott
TypeBroad incumbent
Description

Global medical device incumbent with a structural heart and electrophysiology portfolio (including Amplatzer and EP catheters) that competes with cardiac surgery and LAA management markets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SentreHEART

Cardiac Medical Devicessentreheart.com

SentreHEART firmographics

Firmographics
Name
SentreHEART
Legal name
AtriCure, Inc.
Website
https://sentreheart.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

SentreHEART industry classification

Industry
Product category
Cardiac Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHALAD
Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Cardiac medical devices
  • Tissue closure solutions
  • Remotely delivered sutures
  • Surgical closure devices
  • Atrial appendage management

Where SentreHEART is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Markets served

SentreHEART business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Distribution channels1 record

Marketing channels6 records

SentreHEART product offering

Product offering

Core offering

SentreHEART is a medical device company developing tissue closure solutions that give physicians control over remotely delivered sutures. The company focuses on cardiac intervention devices, including hybrid atrial fibrillation therapy devices, epicardial access instruments, and left atrial appendage management products used during cardiac surgery and electrophysiology procedures.

Product overview

AtriCure offers a comprehensive portfolio of medical devices for cardiac surgery focused on two main therapy areas: atrial fibrillation (AFib) treatment and post-operative pain management. The product portfolio includes ablation systems (radiofrequency and cryoablation), left atrial appendage management devices (AtriClip family), and cryo nerve block probes for pain management. Key product lines include the Isolator Synergy ablation clamps and pens, cryoICE cryoablation systems, the EPi-Sense device for Hybrid AF Therapy, and the full AtriClip device family for left atrial appendage exclusion. The company also provides minimally invasive surgical instruments and a Multifunctional Ablation Generator (MAG). The portfolio is organized around therapy platforms: Concomitant Surgical Ablation, Hybrid AF Therapy, Hybrid Total Thoracoscopic Therapy, Cryo Nerve Block Therapy, and Left Atrial Appendage Management (LAAM).

Differentiator

Problem solved

Functional benefit

Brands

  • cryoICE: Cryoablation probes for surgical procedures
  • cryoSPHERE
  • AtriClip
  • Isolator
  • EPi-Sense
  • Hybrid AF Therapy
  • cryoFORM
  • cryoXT

Products and services

  • EPi-Sense Device

Companies that use SentreHEART

Customer profile

Segments1 record

Ideal customer profiles1 record

SentreHEART technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

SentreHEART partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights2 records

SentreHEART competitors and assessment

Company assessment

Others

  • Stereotaxis: Robotic magnetic navigation system provider for cardiac ablation procedures, supplying enabling technology to electrophysiology labs where SentreHEART's closure devices may be deployed.

Emerging players

  • Occlutech: Specialist structural heart occlusion company developing LAA and other cardiac closure devices, providing a direct emerging competitor in the same closure-device category as SentreHEART.
  • Conformal Medical: Private LAA closure developer (CLAAS system) competing in the same left-atrial appendage closure space as SentreHEART with a next-generation conformable device design.
  • Cardia (cardiacDimensions): Structural heart company developing implant-based devices for cardiovascular applications; a comparable small-stage developer with niche mechanical solutions addressing cardiac procedural needs.

Broad incumbents

  • Medtronic: World-leading cardiovascular device company with electrophysiology, surgical ablation, and cardiac rhythm management businesses directly adjacent to SentreHEART's procedural domain.
  • Boston Scientific: Large-cap medical device company whose Watchman is the market-leading endocardial LAA closure device, addressing the same stroke-prevention unmet need served by SentreHEART's closure technology.
  • Johnson & Johnson (Biosense Webster): Biosense Webster is the dominant electrophysiology franchise globally; competes in ablation and LAA management pipelines that overlap with SentreHEART's target procedures.
  • AtriCure: NASDAQ-listed atrial fibrillation and pain management medical device company; competes directly in LAA exclusion (AtriClip) and surgical ablation and is the only natural strategic acquirer given its overlap with SentreHEART's tissue-closure focus.
  • Abbott: Global medical device incumbent with a structural heart and electrophysiology portfolio (including Amplatzer and EP catheters) that competes with cardiac surgery and LAA management markets.

Regional players

  • Lifetech Scientific: China-based cardiovascular and structural heart device company with an LAA occluder line (LAmbre) covering the same clinical indication served by SentreHEART, primarily in the Asia-Pacific market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key highlights5 records

Customer concentration

SentreHEART social profiles

Digital presence

SentreHEART financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SentreHEART leadership team

Management profile

Number of profiles

Profiles1 record

SentreHEART subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

SentreHEART funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SentreHEART M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SentreHEART

What does SentreHEART do?

SentreHEART is a medical device company developing tissue closure solutions that give physicians control over remotely delivered sutures. The company focuses on cardiac intervention devices, including hybrid atrial fibrillation therapy devices, epicardial access instruments, and left atrial appendage management products used during cardiac surgery and electrophysiology procedures.

Is SentreHEART a public or private company?

SentreHEART is a public company. It is classified as venture growth investor backed and is currently operating.

When was SentreHEART founded?

SentreHEART was founded in 2005. It employs 51 to 100 people.

Where is SentreHEART based?

SentreHEART is headquartered in Redwood City, United States, in the North America region.

Who are SentreHEART's main competitors?

Stereotaxis is listed as an others. Emerging players are Occlutech, Conformal Medical and Cardia (cardiacDimensions). Broad incumbents are Medtronic, Boston Scientific, Johnson & Johnson (Biosense Webster), AtriCure and Abbott. Lifetech Scientific is listed as a regional player.

Does SentreHEART have an API?

No public API is recorded for SentreHEART.

What industry is SentreHEART in?

SentreHEART's product category is Cardiac Medical Devices. Its primary akta.pro industry code is HLAHAFAH, Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts), with a secondary code of HLAHALAD, Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0AtriCure Buying SentreHEART For Up To $300 Million: Details About The Deal You Should KnowAtriCure agreed to acquire SentreHEART for up to $300 million, including a $40 million upfront payment and contingent consideration. The deal includes $140 million for aMAZE IDE trial milestones and $120 million for reimbursement milestones. AtriCure expects a short-term EBITDA loss of $7-9 million in 2019.PR NewswireResearch and Markets - Global Left Atrial Appendage Closure Market Growth at CAGR of 33.54% by 2021, with AtriCure, Boston Scientific, Coherex Medical & St. Jude Medical DominatingResearch and Markets announced a report on the global left atrial appendage closure market, projecting a CAGR of 33.54% from 2017 to 2021. The market is driven by rising atrial fibrillation cases, with key vendors including AtriCure, Boston Scientific, Coherex Medical, and St. Jude Medical.VC News DailySentreHEART Announces $35M Series D RoundSentreHEART, a medical device company based in Redwood City, California, announced the close of a $35 million Series D financing round led by Deerfield Management Company, with participation from existing investors U.S. Venture Partners, Prospect Ventures, Vivo Capital, and Decheng Capital. The funding will support completion of the aMAZE randomized pivotal clinical trial evaluating the LARIAT device for left atrial appendage closure as an adjunctive treatment to ablation in patients with persistent or longstanding persistent atrial fibrillation. As part of the investment, Deerfield Partner Ted Huber will join SentreHEART's Board of Directors.